Confronto

Pasireotid vs. Triptorelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

396091-73-9

57773-63-4

Peso molecolare

1047.21 g/mol

1311.45 g/mol

Emivita

nessun dato

3 h

Sequenza

nessun dato

pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

Meccanismo d'azione

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Triptorelin

Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Pasireotid	Triptorelin
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Pasireotid and Triptorelin?: Pasireotid is classified as "Ricerca (altro)", while Triptorelin is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Triptorelin?: The highest available evidence level is "RCT sull'uomo" for Pasireotid and "RCT sull'uomo" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Triptorelin in Germany and the United States?: Germania: Pasireotid — Su prescrizione, Triptorelin — Su prescrizione. Stati Uniti: Pasireotid — Su prescrizione, Triptorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Triptorelin

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Pasireotid and Triptorelin?

Pasireotid is classified as "Ricerca (altro)", while Triptorelin is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Triptorelin?

The highest available evidence level is "RCT sull'uomo" for Pasireotid and "RCT sull'uomo" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Triptorelin in Germany and the United States?

Germania: Pasireotid — Su prescrizione, Triptorelin — Su prescrizione. Stati Uniti: Pasireotid — Su prescrizione, Triptorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.